GNFT
Genfit S.A.
NASDAQ · Healthcare · Biotechnology · FR
$8.95
+4.07%Year over year
Reported trailing growth
- Revenue
- +9.8%
- EBITDA
- —
- EBIT
- -97.0%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.8%
- EBITDA
- -37.9%
- EBIT
- -53.1%
- Net income
- -71.8%
- EPS
- -72.9%
- Free cash flow
- -47.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025